Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

IVAX BEGINS SHIPMENTS OF GENERIC ALBUTEROL MDI IMMEDIATELY FOLLOWING DEC. 28 ANDA APPROVAL; BIOEQUIVALENCE TO VENTOLIN SHOWN IN IN VIVO TESTS, FDA SAYS

  • News

Executive Summary

Ivax began shipping its generic version of Glaxo's Ventolin metered-dose inhaler on Dec. 29, less than 24 hours following FDA approval of the ANDA for the albuterol product. The company will market the product approved Dec. 28 through its Zenith Goldine subsidiary. Ivax is understood to have 2 mil. cannisters ready for shipping.

Table

View full table

Tags:
Latest Headlines

Medicare Negotiation Second Cycle Draft Guidance Offers Options For ‘Effectuating’ Prices

Medicare Negotiation Timeline For Prices To Be Implemented In 2027

What’s The Key To Successful R&D With Artificial Intelligence? ‘Bilingual’ Scientists

Pink Sheet Podcast: US FDA Adcomm Reform, Clinical Trial Modeling Boost, AI For Drug Review

See All
UsernamePublicRestriction

Register

PS027428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By